Ghorab Rasha Ahmed, Fouad Shaimaa H, Sherief Ahmed F, Taha Rana M, Hamdy Marwa, Darwish Mohammad M, El-Sehsah Eman M, Taha Sara I
Department of Clinical Pathology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Department of Internal Medicine/Allergy and Clinical Immunology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Innate Immun. 2024 Dec 23:17534259241308661. doi: 10.1177/17534259241308661.
Globally, colorectal cancer (CRC) is among the most prevalent malignant tumors. It is characterized by unlimited proliferation, invasion, and metastasis. MicroRNA-126 (miR-126) has been shown in many studies to play a significant role in CRC, but data regarding its role in CRC Egyptian patients are limited.
This case-control study aimed to investigate the miR-126 as a potential marker in CRC Egyptian patients and to correlate its expression levels with CRC tumor, node, metastasis (TNM) stage, distant metastasis, and tumor size.
The study included 50 adult Egyptian participants (30 patients with CRC, 10 patients with colorectal adenoma as a pathological control, and 10 healthy controls). MiR-126 expression levels were detected using Real-Time Quantitative PCR (qPCR) along with the endogenous reference gene hsa-miR-103a in all participants.
MiR-126 expression was significantly decreased in CRC patients than both control groups. It was associated with advanced TNM stage (= 0.001) and distant metastasis (= 0.002). However, it was not correlated with tumor size (= 0.980), carcinoembryonic antigen (CEA) (= 0.397), and cancer antigen 19-9 (CA19-9) (= 0.236). The best cut-off point of miR-126 to discriminate CRC from both controls was 0.7 and to discriminate metastatic CRC from non-metastatic CRC was 0.3.
Our results suggest that miR-126 could be used as an early marker for CRC detection among Egyptian patients and a good prognostic indicator associated with metastasis.
在全球范围内，结直肠癌（CRC）是最常见的恶性肿瘤之一。其特征为无限增殖、侵袭和转移。许多研究表明，MicroRNA - 126（miR - 126）在结直肠癌中发挥着重要作用，但关于其在埃及结直肠癌患者中的作用的数据有限。
本病例对照研究旨在调查miR - 126作为埃及结直肠癌患者潜在标志物的情况，并将其表达水平与结直肠癌的肿瘤、淋巴结、转移（TNM）分期、远处转移及肿瘤大小相关联。
该研究纳入了50名成年埃及参与者（30例结直肠癌患者、10例大肠腺瘤患者作为病理对照以及10名健康对照）。在所有参与者中，使用实时定量聚合酶链反应（qPCR）并结合内参基因hsa - miR - 103a检测miR - 126的表达水平。
与两个对照组相比，结直肠癌患者中miR - 126的表达显著降低。它与晚期TNM分期（= 0.001）和远处转移（= 0.002）相关。然而，它与肿瘤大小（= 0.980）、癌胚抗原（CEA）（= 0.397）和癌抗原19 - 9（CA19 - 9）（= 0.236）无关。区分结直肠癌与两个对照组的miR - 126最佳截断点为0.7，区分转移性结直肠癌与非转移性结直肠癌的最佳截断点为0.3。
我们的结果表明，miR - 126可作为埃及患者结直肠癌检测的早期标志物以及与转移相关的良好预后指标。
